Funds holding Esperion Therapeutics Inc
ISIN US29664W1053 · United States · LEI 549300OFU56UKEWVUS92
- Fund holders
- 104
- Of which ETFs
- 23 81 other funds
- Value held
- ≈ 134.6M $ 134.5M $ · 157.4K €
- Share of capital
- 16.5 % of 257.4M shares on Apr 30, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| ProShares Hedge Replication ETF ProShares Trust | 225 | 704.3 $ | 0.00 % | 0.00 % | as of May 31, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 72 | 227.5 $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 71 | 222.2 $ | 0.02 % | 0.00 % | as of May 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 157.4K € | 0.19 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| ProShares Merger ETF ProShares Trust | 2.34 % | as of May 31, 2026 ↗ |
| AltShares Merger Arbitrage ETF AltShares Trust | 1.84 % | as of May 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 1.54 % | as of Jun 30, 2026 ↗ |
| PROFUND VP PHARMACEUTICALS ProFunds | 1.49 % | as of Jun 30, 2026 ↗ |
| Wasatch Ultra Growth Fund WASATCH FUNDS TRUST | 1.26 % | as of Jun 30, 2026 ↗ |
| Comstock Capital Value Fund Comstock Funds, Inc. | 1.21 % | as of Jun 30, 2026 ↗ |
| Nexpoint Merger Arbitrage Fund NexPoint Funds I | 0.57 % | as of Jun 30, 2026 ↗ |
| Enterprise Mergers and Acquisitions Fund Gabelli 787 Fund, Inc. | 0.39 % | as of Jun 30, 2026 ↗ |
| The Gabelli ABC Fund Gabelli Investor Funds Inc | 0.32 % | as of Jun 30, 2026 ↗ |
| 1290 VT GAMCO Mergers & Acquisitions Portfolio EQ Advisors Trust | 0.32 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 103 | -32 | 42,604,496 | -12.6 % |
| 2026Q2 | 135 | -3 | 48,757,672 | +7.1 % |
| 2026Q1 | 138 | +20 | 45,535,191 | +24.9 % |
| 2025Q4 | 118 | +14 | 36,445,797 | +3.8 % |
| 2025Q3 | 104 | -9 | 35,108,788 | -8.0 % |
| 2025Q2 | 113 | -7 | 38,150,848 | -19.2 % |
| 2025Q1 | 120 | +2 | 47,220,764 | -0.3 % |
| 2024Q4 | 118 | +55 | 47,383,312 | +40.3 % |
| 2024Q3 | 63 | +29 | 33,778,180 | +87.9 % |
| 2024Q2 | 34 | -7 | 17,976,070 | +27.1 % |
| 2024Q1 | 41 | -1 | 14,139,617 | -9.8 % |
| 2023Q4 | 42 | 15,679,901 |
Institutional managers
201 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 17,852,427 | 48.9M $ | as of Mar 31, 2026 |
| WASATCH ADVISORS LP | 15,768,897 | 43.2M $ | as of Mar 31, 2026 |
| Two Seas Capital LP | 11,394,833 | 31.2M $ | as of Mar 31, 2026 |
| ORBIMED ADVISORS LLC | 10,570,300 | 29M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 9,458,779 | 25.9M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 7,075,083 | 19.4M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 7,055,794 | 19.3M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 6,540,785 | 17.9M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 5,955,739 | 16.3M $ | as of Mar 31, 2026 |
| AIGH Capital Management LLC | 4,400,000 | 12.1M $ | as of Mar 31, 2026 |
| UBS Group AG | 4,291,711 | 11.8M $ | as of Mar 31, 2026 |
| ARMISTICE CAPITAL, LLC | 3,930,125 | 10.8M $ | as of Mar 31, 2026 |
| PenderFund Capital Management Ltd. | 3,891,926 | 10.7M $ | as of Mar 31, 2026 |
| Nuveen, LLC | 3,613,709 | 9.9M $ | as of Mar 31, 2026 |
| Privium Fund Management B.V. | 3,299,441 | 9M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 2,735,644 | 7.5M $ | as of Mar 31, 2026 |
| ROYCE & ASSOCIATES LP | 2,626,995 | 7.2M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 2,410,454 | 6.6M $ | as of Mar 31, 2026 |
| JONES FINANCIAL COMPANIES LLLP | 2,135,741 | 5.9M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 2,104,008 | 5.8M $ | as of Mar 31, 2026 |
| Voleon Capital Management LP | 1,916,698 | 5.3M $ | as of Mar 31, 2026 |
| Eversept Partners, LP | 1,735,963 | 4.8M $ | as of Mar 31, 2026 |
| Velan Capital Investment Management LP | 1,720,000 | 4.7M $ | as of Mar 31, 2026 |
| Point72 Asset Management, L.P. | 1,689,372 | 4.6M $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 1,620,100 | 4.4M $ | as of Mar 31, 2026 |
Declared shareholders of Esperion Therapeutics Inc
There are 3 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. and 1 other | 6.70 % | 17,222,156 | as of Jun 30, 2026 · SCHEDULE 13G |
| Vanguard Capital Management | 5.08 % | 13,105,104 | as of Jun 30, 2026 · SCHEDULE 13G |
| Wasatch Advisors LP | 0.70 % | 1,930,185 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Esperion Therapeutics Inc". https://titelia.com/en/stocks/esperion-therapeutics-inc-US29664W1053